The European Medicines Agency is encouraging developers of antimicrobial resistance (AMR) therapies to consider applying for designation under its priority medicines (PRIME) scheme for getting medicines for unmet medical needs to patients faster.
There have been around 100 applications for PRIME so far, but none of them are for an investigational product for AMR, according to Robert Hemmings, chair of the EMA’s Scientific...